Success Metrics

Clinical Success Rate
80.5%

Based on 588 completed trials

Completion Rate
81%(588/730)
Active Trials
227(19%)
Results Posted
71%(415 trials)
Terminated
142(12%)

Phase Distribution

Ph not_applicable
51
4%
Ph phase_1
213
18%
Ph phase_2
514
44%
Ph phase_4
111
9%
Ph early_phase_1
12
1%
Ph phase_3
257
22%

Phase Distribution

225

Early Stage

514

Mid Stage

368

Late Stage

Phase Distribution1158 total trials
Early Phase 1First-in-human
12(1.0%)
Phase 1Safety & dosage
213(18.4%)
Phase 2Efficacy & side effects
514(44.4%)
Phase 3Large-scale testing
257(22.2%)
Phase 4Post-market surveillance
111(9.6%)
N/ANon-phased studies
51(4.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.3%

588 of 781 finished

Non-Completion Rate

24.7%

193 ended early

Currently Active

227

trials recruiting

Total Trials

1,175

all time

Status Distribution
Active(271)
Completed(588)
Terminated(193)
Other(123)

Detailed Status

Completed588
Terminated142
Recruiting123
unknown117
Active, not recruiting104
Withdrawn51

Development Timeline

Analytics

Development Status

Total Trials
1175
Active
227
Success Rate
80.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 112 (1.0%)
Phase 1213 (18.4%)
Phase 2514 (44.4%)
Phase 3257 (22.2%)
Phase 4111 (9.6%)
N/A51 (4.4%)

Trials by Status

unknown11710%
active_not_recruiting1049%
not_yet_recruiting393%
terminated14212%
enrolling_by_invitation50%
recruiting12310%
suspended61%
completed58850%
withdrawn514%

Recent Activity

Clinical Trials (1,175)

Showing 20 of 1,175 trialsScroll for more
NCT03419234Phase 2

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Active Not Recruiting
NCT05675410Phase 3

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Recruiting
NCT07712588Phase 2

Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)

Not Yet Recruiting
NCT06649812Phase 2

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Recruiting
NCT04803201Phase 2

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Suspended
NCT06660355Phase 2

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Recruiting
NCT07746245Phase 2

The Efficacy of CAPCT in Patients With PTCL

Not Yet Recruiting
NCT05039619Phase 2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Recruiting
NCT06124157Phase 2

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting
NCT05176483Phase 1

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Recruiting
NCT03984448Phase 2

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Active Not Recruiting
NCT06191744Phase 3

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Active Not Recruiting
NCT02003222Phase 3

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT02143414Phase 2

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT00092222Phase 2

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Active Not Recruiting
NCT03920007Phase 1

Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D

Active Not Recruiting
NCT06624670Phase 3

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Recruiting
NCT02960022Phase 2

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Recruiting
NCT06934915Early Phase 1

Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder

Recruiting
NCT04530565Phase 3

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
1,175